The	O
anti-apoptotic	B:C1512772
PON2	B:C0755726
protein	I:C0755726
is	O
Wnt	B:C0753137
/	O
β-	B:C0105770
catenin	I:C0105770
-	O
regulated	B:C1327622
and	O
correlates	O
with	O
radiotherapy	B:C1522449
resistance	O
in	O
OSCC	O
patients	O
.	O

Wnt	B:C1520113
signaling	I:C1520113
and	O
control	O
of	O
anti-apoptotic	B:C1512772
mechanisms	O
are	O
pivotal	O
features	O
in	O
different	O
types	O
of	O
cancer	B:C0006826
to	O
undergo	O
cell	B:C0007587
death	I:C0007587
programs	O
.	O

The	O
intracellular	B:C0178719
human	B:C0086418
enzyme	B:C0014442
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
(	O
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
)	O
is	O
known	O
to	O
have	O
anti-apoptotic	B:C1512772
properties	O
in	O
leukemia	B:C0023418
and	O
oral	O
squamous	O
cell	O
cancer	O
(	O
OSCC	O
)	O
cells	B:C0007634
.	O

However	O
,	O
the	O
distinct	O
regulating	B:C1327622
pathways	O
are	O
poorly	O
understood	O
.	O

First	O
,	O
we	O
present	O
a	O
so	O
far	O
unknown	O
regulation	B:C1327622
of	O
PON2	B:C0755726
protein	I:C0755726
expression	B:C1171362
through	O
the	O
Wnt	B:C1520113
/	O
GSK3	B:C0244988
β	I:C0244988
/	O
β-	B:C0105770
catenin	I:C0105770
pathway	B:C1704259
in	O
leukemia	B:C0023418
and	O
OSCC	O
cells	B:C0007634
.	O

This	O
was	O
confirmed	O
via	O
in	O
silico	B:C0936012
analysis	I:C0936012
,	O
promoter	B:C0242481
reporter	I:C0242481
studies	I:C0242481
and	O
treatment	B:C0087111
of	O
multiple	O
cell	B:C0007600
lines	I:C0007600
(	O
K562	B:C1517631
,	O
SCC	B:C0007634
-	I:C0007634
4	I:C0007634
,	O
PCI	B:C0007634
-	I:C0007634
13	I:C0007634
)	O
with	O
different	O

Wnt	B:C0753137
ligands	B:C1749457
/	O
inhibitors	B:C0243077
in	O
vitro	O
.	O

Ex	O
vivo	O
analysis	B:C0936012
of	O
OSCC	O
patients	O
revealed	O
a	O
correlation	O
between	O
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
and	O
β-	B:C0105770
catenin	I:C0105770
expression	B:C1171362
in	O
tumor	B:C0475358
tissue	I:C0475358
.	O

Higher	O
Paraoxonase	B:C0755726
-	I:C0755726
2	I:C0755726
expression	B:C1171362
in	O
OSCC	O
is	O
associated	O
with	O
relapse	O
independently	O
of	O
treatment	B:C0087111
(	O
e.g.	O
surgery	B:C0543467
/	O
radio	B:C1522449
-/	O
chemotherapy	B:C3665472
)	O
.	O

These	O
results	O
emphasize	O
the	O
clinical	O
impact	O
of	O
the	O
newly	O
described	O
regulation	B:C1327622
of	O
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
through	O
Wnt	B:C0753137
/	O
GSK3	B:C0244988
β	I:C0244988
/	O
β-catenin	B:C0105770
.	O

More	O
importantly	O
,	O
the	O
study	O
revealed	O
the	O
fundamental	B:C0243095
finding	I:C0243095
of	O
an	O
overall	O
Wnt	B:C0753137
/	O
GSK3	B:C0244988
β	I:C0244988
/	O
β-	B:C0105770
catenin	I:C0105770
dependent	O
regulation	B:C1327622
of	O
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
in	O
different	O
cancers	B:C0006826
,	O
which	O
was	O
confirmed	O
by	O
systematic	O
and	O
multimethodological	B:C0969625
approaches	O
.	O

Thus	O
,	O
the	O
herein	O
presented	O
mechanistic	O
insight	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
tumor	B:C0027651
specific	O
escape	O
from	O
cell	B:C0007587
death	I:C0007587
strategies	O
and	O
suggests	O
Paraoxonase	B:C1122373
-	I:C1122373
2	I:C1122373
as	O
a	O
new	O
potential	O
biomarker	B:C0005516
for	O
therapy	B:C0087111
resistance	O
or	O
as	O
a	O
prognostic	B:C0220901
tumor	B:C0041365
marker	I:C0041365
.	O

